Current Rheumatology Reports最新文献

How to Distinguish Non-Inflammatory from Inflammatory Pain in RA? 如何区分 RA 中的非炎症性疼痛和炎症性疼痛？

IF 5.7 2区医学

Current Rheumatology Reports Pub Date : 2024-12-01 Epub Date: 2024-08-09 DOI: 10.1007/s11926-024-01159-4

Sharmila Khot, George Tackley, Ernest Choy

{"title":"How to Distinguish Non-Inflammatory from Inflammatory Pain in RA?","authors":"Sharmila Khot, George Tackley, Ernest Choy","doi":"10.1007/s11926-024-01159-4","DOIUrl":"10.1007/s11926-024-01159-4","url":null,"abstract":"Purpose of the review: Managing non-inflammatory pain in rheumatoid arthritis (RA) can be a huge burden for the rheumatologist. Pain that persists despite optimal RA treatment is extremely challenging for patient and physician alike. Here, we outline the latest research relevant to distinguishing non-inflammatory from inflammatory RA pain and review the current understanding of its neurobiology and management.Recent findings: Nociplastic pain is a recently introduced term by the international pain community. Its definition encompasses the non-inflammatory pain of RA and describes pain that is not driven by inflamed joints or compromised nerves, but that is instead driven by a functional reorganisation of the central nervous system (CNS). Insights from all areas of nociplastic pain research, including fibromyalgia, support a personalised pain management approach for non-inflammatory pain of RA, with evidence-based guidelines favouring use of non-pharmacological interventions. Future developments include novel CNS targeting pharmacotherapeutic approaches to treat nociplastic pain.","PeriodicalId":10761,"journal":{"name":"Current Rheumatology Reports","volume":" ","pages":"403-413"},"PeriodicalIF":5.7,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11527911/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141906166","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Treatment of Reactive Arthritis with Biological Agents. 用生物制剂治疗反应性关节炎。

IF 5.7 2区医学

Current Rheumatology Reports Pub Date : 2024-12-01 Epub Date: 2024-09-23 DOI: 10.1007/s11926-024-01165-6

Avarna Agarwal, Debashis Maikap, Prasanta Padhan

{"title":"Treatment of Reactive Arthritis with Biological Agents.","authors":"Avarna Agarwal, Debashis Maikap, Prasanta Padhan","doi":"10.1007/s11926-024-01165-6","DOIUrl":"10.1007/s11926-024-01165-6","url":null,"abstract":"Purpose of the review: Reactive arthritis (ReA) is an inflammatory joint condition triggered by an infection elsewhere in the body, and this review aims to provide a comprehensive synthesis of recent studies including case reports and case series to determine whether biologics are a treatment option.Recent findings: Recent studies indicate that biological agents, including anti-TNF agents (infliximab, adalimumab, etanercept), anti-IL17 (secukinumab), and anti-IL6 (tocilizumab), are effective in treating refractory cases of ReA. Evidence suggests these agents are associated with significant clinical improvement. Notably, the data reveal that these biologics are generally well-tolerated, with a low incidence of major adverse events, which supports their safety profile for use in ReA. Biological agents, including anti-TNF, anti-IL17, and anti-IL6 therapies, can be safely and effectively used in the treatment of ReA when conventional therapies fail. It further emphasizes the need for a well-designed controlled trial to provide scientific basis for better informed clinical decisions in cases not responding to conventional treatment.","PeriodicalId":10761,"journal":{"name":"Current Rheumatology Reports","volume":" ","pages":"450-458"},"PeriodicalIF":5.7,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142281516","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Rheumatoid Arthritis-Associated Interstitial Lung Disease (RA-ILD): Update on Prevalence, Risk Factors, Pathogenesis, and Therapy. 类风湿性关节炎相关间质性肺病（RA-ILD）：发病率、风险因素、发病机制和治疗的最新进展。

IF 5.7 2区医学

Current Rheumatology Reports Pub Date : 2024-12-01 Epub Date: 2024-09-25 DOI: 10.1007/s11926-024-01155-8

Daniel I Sullivan, Dana P Ascherman

{"title":"Rheumatoid Arthritis-Associated Interstitial Lung Disease (RA-ILD): Update on Prevalence, Risk Factors, Pathogenesis, and Therapy.","authors":"Daniel I Sullivan, Dana P Ascherman","doi":"10.1007/s11926-024-01155-8","DOIUrl":"10.1007/s11926-024-01155-8","url":null,"abstract":"Purpose of review: Rheumatoid arthritis is frequently complicated by interstitial lung disease (RA-ILD), an underappreciated contributor to excess morbidity and mortality. The true prevalence of RA-ILD is difficult to define given the variability in diagnostic criteria used. The lack of standardized screening methods, an incomplete understanding of disease pathogenesis, and dearth of validated biomarkers have limited the development of controlled clinical trials for this disease.Recent findings: Numerous studies have focused on clinical, radiographic, genetic, molecular, and/or serologic markers of disease severity as well as risk of disease progression. In addition to defining valuable clinical biomarkers, these studies have provided insights regarding the pathogenesis of RA-ILD and potential therapeutic targets. Additional studies involving immunomodulatory and/or anti-fibrotic agents have assessed new therapeutic options for different stages of RA-ILD. RA-ILD continues to be a major contributor to the increased morbidity and mortality associated with RA. Advancements in our understanding of disease pathogenesis at a molecular level are necessary to drive the development of more targeted therapy.","PeriodicalId":10761,"journal":{"name":"Current Rheumatology Reports","volume":" ","pages":"431-449"},"PeriodicalIF":5.7,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142343110","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Telemedicine for the Care of Patients with Idiopathic Inflammatory Myopathies: Experience, Insights and Future Directions from the International Myositis Assessment and Clinical Studies Telemedicine Scientific Interest Group. 远程医疗用于特发性炎症性肌病患者的护理：国际肌炎评估和临床研究远程医疗科学兴趣小组的经验、见解和未来方向。

IF 5.7 2区医学

Current Rheumatology Reports Pub Date : 2024-12-01 Epub Date: 2024-08-31 DOI: 10.1007/s11926-024-01163-8

Jessica Day, Hani Kushlaf, Stacey Tarvin, Lorenzo Cavagna, Veronica Codullo, Samuel Katsuyuki Shinjo, Xia Lyu, Johannes Knitza, Raouf Hajji, Peter R Blier, Chih Wei Tseng, Simone Appenzeller, Lisa G Rider, Lisa Christopher-Stine, Latika Gupta

引用次数: 0

Recent Updates on the Pathogenesis of Inflammatory Myopathies. 炎症性肌病发病机制的最新进展。

IF 5.7 2区医学

Current Rheumatology Reports Pub Date : 2024-12-01 Epub Date: 2024-09-24 DOI: 10.1007/s11926-024-01164-7

Jon Musai, Andrew L Mammen, Iago Pinal-Fernandez

{"title":"Recent Updates on the Pathogenesis of Inflammatory Myopathies.","authors":"Jon Musai, Andrew L Mammen, Iago Pinal-Fernandez","doi":"10.1007/s11926-024-01164-7","DOIUrl":"10.1007/s11926-024-01164-7","url":null,"abstract":"Purpose of review: This review aims to provide a comprehensive and updated overview of autoimmune myopathies, with a special focus on the latest advancements in understanding the role of autoantibodies. We will begin by examining the risk factors and triggers associated with myositis. Next, we will delve into recent research on how autoantibodies contribute to disease pathogenesis. Finally, we will explore the latest innovations in treatment strategies and their implications for our understanding of myositis pathogenesis.Recent findings: Recent research has revealed that myositis-specific autoantibodies can infiltrate muscle cells and disrupt the function of their target autoantigens, playing a crucial role in disease pathogenesis. Significant advances in treatment include CD19 CAR-T cell therapy, JAK-STAT inhibitors, and novel strategies targeting the type 1 interferon pathway in dermatomyositis. Additionally, the ineffectiveness of complement inhibitors in treating immune-mediated necrotizing myositis has challenged established views on disease mechanisms. Autoimmune myopathies are a collection of disorders significantly influenced by specific autoantibodies that drive disease pathogenesis. This review highlights the critical role of autoantibody research in deepening our understanding of these conditions and discusses recent therapeutic advancements targeting key pathogenic pathways.","PeriodicalId":10761,"journal":{"name":"Current Rheumatology Reports","volume":" ","pages":"421-430"},"PeriodicalIF":5.7,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11527972/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142307313","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Digital Health and Self-Management in Idiopathic Inflammatory Myopathies: A Missed Opportunity? 特发性炎症性肌病的数字健康与自我管理：错失良机？

IF 5.7 2区医学

Current Rheumatology Reports Pub Date : 2024-11-01 Epub Date: 2024-08-08 DOI: 10.1007/s11926-024-01157-6

Simone Battista, Benedetto Giardulli, Cristiana Sieiro Santos, Or Aharonov, Darshan Puttaswamy, Anne -Marie Russell, Latika Gupta

{"title":"Digital Health and Self-Management in Idiopathic Inflammatory Myopathies: A Missed Opportunity?","authors":"Simone Battista, Benedetto Giardulli, Cristiana Sieiro Santos, Or Aharonov, Darshan Puttaswamy, Anne -Marie Russell, Latika Gupta","doi":"10.1007/s11926-024-01157-6","DOIUrl":"10.1007/s11926-024-01157-6","url":null,"abstract":"Purpose of review: This paper explored the potential of digital health in idiopathic inflammatory myopathies (IIMs), with a focus on self-management. Digital self-management technology includes tailored treatment plans, symptom tracking, educational resources, enhanced communication, and support for long-term planning.Recent findings: After arguing the importance of digital health in IIMs management, from diagnosis until treatment, our literature review revealed a notable gap in research focusing on the efficacy of digital self-management interventions for individuals with IIMs, with no randomised controlled trials or observational studies addressing this topic. Our review further highlighted the significant unmet need for research in self-management interventions for individuals with IIMs. The absence of studies underscores the necessity for collaborative efforts to address this gap and develop personalised, effective strategies for managing IIMs using digital technology. Individuals with IIMs deserve tailored self-management approaches akin to those available for other rheumatic and musculoskeletal diseases.","PeriodicalId":10761,"journal":{"name":"Current Rheumatology Reports","volume":" ","pages":"383-391"},"PeriodicalIF":5.7,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11469974/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141901194","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Calcium Pyrophosphate Crystal Deposition: Insights to Risks Factors and Associated Conditions. 焦磷酸钙晶体沉积：洞察风险因素和相关条件。

IF 5.7 2区医学

Current Rheumatology Reports Pub Date : 2024-11-01 Epub Date: 2024-08-05 DOI: 10.1007/s11926-024-01158-5

Konstantinos Parperis, Argyris Constantinou

{"title":"Calcium Pyrophosphate Crystal Deposition: Insights to Risks Factors and Associated Conditions.","authors":"Konstantinos Parperis, Argyris Constantinou","doi":"10.1007/s11926-024-01158-5","DOIUrl":"10.1007/s11926-024-01158-5","url":null,"abstract":"Purpose of the review: This review provides an overview of medical conditions and risk factors associated with CPPD.Recent findings: Recent studies have indicated that CPPD patients may have a higher risk for systemic conditions such as cardiovascular diseases. Calcium pyrophosphate deposition disease (CPPD) is a common crystal arthropathy that primarily affects older adults, and, in most cases, the aetiology is idiopathic. Age is the most remarkable risk factor and due to the aging population, the prevalence of this condition is expected to increase. Strong evidence supports an association between CPPD and several metabolic and endocrine conditions, including hemochromatosis, hyperparathyroidism, hypomagnesemia, and hypophosphatasia. Additionally, there is growing evidence of an increased risk for cardiovascular diseases among CPPD patients, alongside potential links to rheumatic disorders, gender, medications, and joint trauma. Further research is needed to explore the underlying mechanisms linking CPPD to associated conditions and to develop targeted therapies with the aim of improving patient outcomes.","PeriodicalId":10761,"journal":{"name":"Current Rheumatology Reports","volume":" ","pages":"375-382"},"PeriodicalIF":5.7,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141888718","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The Elusive Truth of Cannabinoids for Rheumatic Pain. 大麻素治疗风湿痛的神秘真相

IF 5.7 2区医学

Current Rheumatology Reports Pub Date : 2024-11-01 Epub Date: 2024-08-09 DOI: 10.1007/s11926-024-01162-9

Hance Clarke, Sarah Miles, Miki Peer, Mary-Ann Fitzcharles

{"title":"The Elusive Truth of Cannabinoids for Rheumatic Pain.","authors":"Hance Clarke, Sarah Miles, Miki Peer, Mary-Ann Fitzcharles","doi":"10.1007/s11926-024-01162-9","DOIUrl":"10.1007/s11926-024-01162-9","url":null,"abstract":"Purpose of review: Medical cannabis (MC) has entered mainstream medicine by a unique route. Regulatory acceptance as a medical product in many jurisdictions has bypassed the traditional evidence-based pathway required for therapies. Easier access to MC, especially related to recreational legalization of cannabis, has led to widespread use by patients for symptom relief of a variety of medical conditions and often without medical oversight. Musculoskeletal pain remains the most common reason for MC use. This review examines real-world issues pertaining to MC and offers some guidance for clinical care of patients with rheumatic diseases being treated with MC.Recent findings: Controlled clinical studies of cannabis products in patients with rheumatic diseases have been small and tested a range of compounds, routes of administration, and clinical populations, limiting our ability to generate conclusions on MC's effectiveness in this population. Observational cohort studies and surveys suggest that use of MC and related products in patients with rheumatic diseases improves pain and associated symptoms but is commonly accompanied by mild to moderate side effects. Conflicting evidence contributes to practitioner and patient uncertainty regarding the use of MC for rheumatic disease-related pain. Despite promising preclinical and observational evidence that MC and cannabis-derived compounds are useful in the management of rheumatic disease-related pain, there remains limited high-quality clinical evidence to substantiate these findings. There are a significant number of clinical trials on this topic currently planned or underway, however, suggesting the next decade may yield more clarity. Nevertheless, given that many people with rheumatic diseases are using cannabis products, healthcare professionals must remain apprised of the evidence pertaining to cannabinoids, communicate such evidence to patients in a meaningful way that is free from personal bias and stigma, and maintain strong collaborative clinical care pertaining to MC.","PeriodicalId":10761,"journal":{"name":"Current Rheumatology Reports","volume":" ","pages":"392-402"},"PeriodicalIF":5.7,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141906167","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Calcium Pyrophosphate Crystal Formation and Deposition: Where Do we Stand and What Does the Future hold? 焦磷酸钙晶体的形成与沉积：我们的现状和未来如何？

IF 5.7 2区医学

Current Rheumatology Reports Pub Date : 2024-10-01 Epub Date: 2024-08-01 DOI: 10.1007/s11926-024-01161-w

Silvia Sirotti, Anna Scanu, Tristan Pascart, Tom Niessink, Paola Maroni, Giovanni Lombardi, Georgios Filippou

{"title":"Calcium Pyrophosphate Crystal Formation and Deposition: Where Do we Stand and What Does the Future hold?","authors":"Silvia Sirotti, Anna Scanu, Tristan Pascart, Tom Niessink, Paola Maroni, Giovanni Lombardi, Georgios Filippou","doi":"10.1007/s11926-024-01161-w","DOIUrl":"10.1007/s11926-024-01161-w","url":null,"abstract":"Purpose of the review: Although calcium pyrophosphate deposition (CPPD) has been known since the 1960s, our understanding of its pathogenesis remains rudimentary. This review aims to illustrate the known mechanisms underlying calcium pyrophosphate (CPP) crystal formation and deposition and explore future directions in research. By examining various perspectives, from basic research to clinical and imaging assessments, as well as new emerging methodologies, we can establish a starting point for a deeper understanding of CPPD pathogenesis.Recent findings: Recent years have seen significant advances in CPPD research, particularly in the clinical field with the development of the 2023 ACR/EULAR classification criteria for CPPD disease, and in imaging with the introduction of the OMERACT ultrasonographic definitions and scoring system. However, progress in basic research has been slower. New laboratory approaches, such as Raman spectroscopy and omics sciences, offer promising insights that may help piece together the puzzle of CPPD. CPPD is a common yet understudied condition. As the population ages and CPPD becomes more prevalent, there is an urgent need to better understand the disease and the mechanisms involved in crystal formation and deposition, in order to improve diagnosis and therapeutic approaches.","PeriodicalId":10761,"journal":{"name":"Current Rheumatology Reports","volume":" ","pages":"354-365"},"PeriodicalIF":5.7,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11377473/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141859259","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Air Pollution and Rheumatoid Arthritis Risk and Progression: Implications for the Mucosal Origins Hypothesis and Climate Change for RA Pathogenesis. 空气污染与类风湿关节炎的风险和进展：粘膜起源假说和气候变化对类风湿关节炎发病机制的影响》。

IF 5.7 2区医学

Current Rheumatology Reports Pub Date : 2024-10-01 Epub Date: 2024-08-02 DOI: 10.1007/s11926-024-01160-x

Katarina J Bade, Kevin T Mueller, Jeffrey A Sparks

{"title":"Air Pollution and Rheumatoid Arthritis Risk and Progression: Implications for the Mucosal Origins Hypothesis and Climate Change for RA Pathogenesis.","authors":"Katarina J Bade, Kevin T Mueller, Jeffrey A Sparks","doi":"10.1007/s11926-024-01160-x","DOIUrl":"10.1007/s11926-024-01160-x","url":null,"abstract":"Purpose of review: The goal of this review paper is to summarize the main research and findings regarding air pollution and its association with the risk and progression of rheumatoid arthritis (RA).Recent findings: The most studied components of air pollution included particulate matter of ≤ 2.5 microns in diameter (PM2.5), PM10, carbon monoxide (CO), nitrogen dioxide (NO2), nitric oxide (NOx), sulfur dioxide (SO2), and ozone (O3). In addition, specific occupations and occupational inhalants have been investigated for RA risk. Several studies showed that increased exposure to air pollutants increased the risk of developing RA, particularly seropositive RA. There was evidence of gene-inhalant interactions for seropositive RA risk. Fewer studies have been conducted on RA disease activity and bone erosions. Some studies suggest that patients with RA-associated interstitial lung disease may have worse outcomes if exposed to air pollution. We summarized associations between air pollution and increased RA risk, including RA-associated interstitial lung disease. Relatively few studies investigated air pollution and RA disease activity or other outcomes. These results suggest an important role of air pollution for seropositive RA development and suggest that climate change could be a driver in increasing RA incidence as air pollution increases.","PeriodicalId":10761,"journal":{"name":"Current Rheumatology Reports","volume":" ","pages":"343-353"},"PeriodicalIF":5.7,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141874374","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0